Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 9, 2024 and accepted by EDGAR at Aug 9, 2024, 20:45 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $8.0k | us-gaap:Revenues |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $8.0k | us-gaap:Revenues |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $3.2k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $3.2k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-04-01 to 2024-06-30 | $4.8k | us-gaap:GrossProfit |
| Gross profit | 6 months2024-01-01 to 2024-06-30 | $4.8k | us-gaap:GrossProfit |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $924.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-04-01 to 2024-06-30 | $676.1k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-01-01 to 2024-06-30 | $1.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$1.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$2.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-04-01 to 2024-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-01-01 to 2024-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$1.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$2.6m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$2.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 6 months2024-01-01 to 2024-06-30 | $149.5k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Current assets | At period end2024-06-30 | $7.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $8.0m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $376.3k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $376.3k | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-30 | $7.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001477932-24-004635. Last ingested by Listed: Oct 24, 2026, 15:10 ET. Listed shows no prices and gives no investment advice.